1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Tuvonralimab Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 50 mg / 2 mL
  • 1.3.3 100 mg / 10 mL
• 1.4 Market Analysis by Route of Administration
  • 1.4.1 Overview: Global Tuvonralimab Consumption Value by Route of Administration: 2021 Versus 2025 Versus 2032
  • 1.4.2 Intravenous Infusion
  • 1.4.3 Intravenous injection
• 1.5 Market Analysis by Combination Medication
  • 1.5.1 Overview: Global Tuvonralimab Consumption Value by Combination Medication: 2021 Versus 2025 Versus 2032
  • 1.5.2 Iparomlimab Combined With Tuvonralimab
  • 1.5.3 Bevacizumab Combination Therapy
• 1.6 Market Analysis by Sales Channels
  • 1.6.1 Overview: Global Tuvonralimab Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
  • 1.6.2 Hospital
  • 1.6.3 Retail
  • 1.6.4 Online
• 1.7 Market Analysis by Application
  • 1.7.1 Overview: Global Tuvonralimab Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.7.2 Cervical Cancer
  • 1.7.3 Hepatocellular Carcinoma
  • 1.7.4 Non-Small Cell Lung Cancer
  • 1.7.5 Others
• 1.8 Global Tuvonralimab Market Size & Forecast
  • 1.8.1 Global Tuvonralimab Consumption Value (2021 & 2025 & 2032)
  • 1.8.2 Global Tuvonralimab Sales Quantity (2021-2032)
  • 1.8.3 Global Tuvonralimab Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 Qilu Pharmaceuticals
  • 2.1.1 Qilu Pharmaceuticals Details
  • 2.1.2 Qilu Pharmaceuticals Major Business
  • 2.1.3 Qilu Pharmaceuticals Tuvonralimab Product and Services
  • 2.1.4 Qilu Pharmaceuticals Tuvonralimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Qilu Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Tuvonralimab by Manufacturer

• 3.1 Global Tuvonralimab Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Tuvonralimab Revenue by Manufacturer (2021-2026)
• 3.3 Global Tuvonralimab Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Tuvonralimab by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Tuvonralimab Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Tuvonralimab Manufacturer Market Share in 2025
• 3.5 Tuvonralimab Market: Overall Company Footprint Analysis
  • 3.5.1 Tuvonralimab Market: Region Footprint
  • 3.5.2 Tuvonralimab Market: Company Product Type Footprint
  • 3.5.3 Tuvonralimab Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Tuvonralimab Market Size by Region
  • 4.1.1 Global Tuvonralimab Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Tuvonralimab Consumption Value by Region (2021-2032)
  • 4.1.3 Global Tuvonralimab Average Price by Region (2021-2032)
• 4.2 North America Tuvonralimab Consumption Value (2021-2032)
• 4.3 Europe Tuvonralimab Consumption Value (2021-2032)
• 4.4 Asia-Pacific Tuvonralimab Consumption Value (2021-2032)
• 4.5 South America Tuvonralimab Consumption Value (2021-2032)
• 4.6 Middle East & Africa Tuvonralimab Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Tuvonralimab Sales Quantity by Type (2021-2032)
• 5.2 Global Tuvonralimab Consumption Value by Type (2021-2032)
• 5.3 Global Tuvonralimab Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Tuvonralimab Sales Quantity by Application (2021-2032)
• 6.2 Global Tuvonralimab Consumption Value by Application (2021-2032)
• 6.3 Global Tuvonralimab Average Price by Application (2021-2032)

7 North America

• 7.1 North America Tuvonralimab Sales Quantity by Type (2021-2032)
• 7.2 North America Tuvonralimab Sales Quantity by Application (2021-2032)
• 7.3 North America Tuvonralimab Market Size by Country
  • 7.3.1 North America Tuvonralimab Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Tuvonralimab Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Tuvonralimab Sales Quantity by Type (2021-2032)
• 8.2 Europe Tuvonralimab Sales Quantity by Application (2021-2032)
• 8.3 Europe Tuvonralimab Market Size by Country
  • 8.3.1 Europe Tuvonralimab Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Tuvonralimab Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Tuvonralimab Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Tuvonralimab Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Tuvonralimab Market Size by Region
  • 9.3.1 Asia-Pacific Tuvonralimab Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Tuvonralimab Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Tuvonralimab Sales Quantity by Type (2021-2032)
• 10.2 South America Tuvonralimab Sales Quantity by Application (2021-2032)
• 10.3 South America Tuvonralimab Market Size by Country
  • 10.3.1 South America Tuvonralimab Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Tuvonralimab Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Tuvonralimab Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Tuvonralimab Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Tuvonralimab Market Size by Country
  • 11.3.1 Middle East & Africa Tuvonralimab Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Tuvonralimab Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Tuvonralimab Market Drivers
• 12.2 Tuvonralimab Market Restraints
• 12.3 Tuvonralimab Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Tuvonralimab and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Tuvonralimab
• 13.3 Tuvonralimab Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Tuvonralimab Typical Distributors
• 14.3 Tuvonralimab Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Tuvonralimab market size was valued at US$ 82.32 million in 2025 and is forecast to a readjusted size of US$ 461 million by 2032 with a CAGR of 10.4% during review period.
Tuvonralimab is a recombinant humanized monoclonal antibody that selectively targets cytotoxic T‑lymphocyte‑associated antigen 4 (CTLA‑4), acting as an immune checkpoint inhibitor to enhance antitumor immunity. By binding specifically to CTLA‑4 receptors on T cells, it blocks inhibitory signals that suppress immune activation, thereby promoting the proliferation and effector function of tumor‑reactive T lymphocytes. Engineered with an optimized immunoglobulin backbone for improved stability and safety, it is commonly developed in combination with PD‑1 inhibitors to achieve synergistic immune activation. As a key component of dual checkpoint combination therapies, tuvonralimab is under clinical evaluation for multiple advanced solid tumors, aiming to overcome immune resistance and improve clinical outcomes in patients with limited treatment options.In 2025, global Tuvonralimab production reached approximately 300,000 vials.
Tuvonralimab targets the advanced solid tumor sector as a dual immune checkpoint combination antibody. Relying on the synergistic blockade mechanism of PD‑1/CTLA‑4 dual targets, it has demonstrated clear clinical value and a solid safety profile in indications such as cervical cancer, making it a representative combination therapy among domestic innovative antibody drugs. Its market development is in the early stage, with core demand driven by unmet medical needs for patients who have failed first‑line treatment or have refractory disease. As clinical research expands to multiple cancer types including liver cancer and lung cancer, it is expected to further broaden the applicable population and prescription scenarios. In terms of competition, the domestic market for similar dual antibodies and immunotherapy combinations is becoming increasingly fierce, and pricing and medical insurance access strategies will significantly affect early penetration. Manufacturers enhance drug accessibility through process optimization and supply chain improvement, while strengthening clinical recognition via academic promotion and real‑world data accumulation, laying a foundation for subsequent market expansion. In the long run, overseas clinical development and international layout will be key to growth, and innovations in combination regimens and biomarker selection will determine its long‑term competitiveness in the complex landscape of cancer treatment.
This report is a detailed and comprehensive analysis for global Tuvonralimab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Tuvonralimab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Tuvonralimab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Tuvonralimab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Tuvonralimab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Tuvonralimab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Tuvonralimab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Qilu Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Tuvonralimab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
50 mg / 2 mL
100 mg / 10 mL
Market segment by Route of Administration
Intravenous Infusion
Intravenous injection
Market segment by Combination Medication
Iparomlimab Combined With Tuvonralimab
Bevacizumab Combination Therapy
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
Cervical Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer
Others
Major players covered
Qilu Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Tuvonralimab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Tuvonralimab, with price, sales quantity, revenue, and global market share of Tuvonralimab from 2021 to 2026.
Chapter 3, the Tuvonralimab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Tuvonralimab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Tuvonralimab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Tuvonralimab.
Chapter 14 and 15, to describe Tuvonralimab sales channel, distributors, customers, research findings and conclusion.